# NeuroLogica Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurologica

- Industry: Medical Devices & Equipment
- Headquarters: Danvers, US
- Website: https://www.neurologica.com/
- Total disclosed funding: $13M
- Latest round: Series D (Jan 10, 2012)
- Investors on record: 1

## About

NeuroLogica Corporation specializes in advanced medical imaging technology, focusing on innovative mobile CT systems that support critical healthcare applications such as interventional radiology and emergency medical services.Founded in 2004 in Danvers, US, NeuroLogica Corporation designs and manufactures mobile CT imaging systems. The company has completed 6 funding deals, with the latest being a Series D round of USD 12.000 mn raised in January 2012 from Stata Venture Partners. Bernard Cohen is the founder, and the current CEO is Samuel Kates.NeuroLogica specializes in advanced medical imaging technology, offering a range of innovative mobile CT products designed to enhance patient care across various medical specialties. Their core offerings include the OmniTom®, BodyTom®, CereTom®, and Photon Counting CT systems, which are engineered to deliver rapid, high-quality imaging for critical healthcare applications such as interventional radiology, pediatrics, neurosurgery, and emergency stroke care. These products facilitate immediate image viewing and improve diagnostic capabilities, thereby minimizing exposure to patients while maximizing safety. NeuroLogica's technology is primarily utilized in hospitals, medical centers, and emergency medical services across multiple geographical markets, including North America, Europe, and select markets in Asia. The company's products are aimed at enhancing workflow efficiency and patient outcomes, positioning them as vital tools in the urgent treatment of cerebrovascular diseases and other medical conditions.NeuroLogica's revenue model is structured around the sale of its proprietary mobile CT systems and associated services, which are typically sold through direct B2B transactions with healthcare institutions. These transactions may involve partnerships with hospitals and medical facilities that seek to enhance their imaging capabilities. The company offers a range of pricing plans tailored to the specific needs of healthcare providers, including options for outright purchases or leasing arrangements. Flagship products such as the OmniTom® and BodyTom® are central to the company's offerings, facilitating a robust sales pipeline. NeuroLogica also provides technical support and training as part of their service model, ensuring that clients can maximize the utility of their imaging systems post-purchase.In January 2012, NeuroLogica Corporation raised USD 12.000 mn in Series D funding, which will be utilized to support the development of upcoming products and expand market penetration. The company is focused on enhancing its imaging technology and plans to introduce new models in the coming years. Additionally, NeuroLogica aims to expand its presence in North America and Europe, with efforts to enter select markets in Asia by 2025.

## Funding rounds

- Series D, Jan 10, 2012, $12M — Stata Venture Partners
- Series B, Sep 25, 2007, $1M — Stata Venture Partners

## Investors

- Stata Venture Partners (https://capitalatlas.ai/funds/stata-venture-partners) — Series B, Series D